|
Showing 1 - 16 of
16 matches in All Departments
This volume represents a collection of contributions from the 6th
International Conference on Eicosanoids and Other Bioactive Lipids
in Cancer, Inflammation, and Related Diseases held in Boston from
September 12-15, 1999. The mission of this meeting was to bring
together senior and junior investigators to both announce and
examine their recent advancements in cutting-edge research on the
roles and actions of lipid mediators and their impact in human
physiology and disease pathogenesis. The meeting focused on new
concepts in these areas of interest to both clinicians and
researchers. The program included several outstanding plenary
lectures and presentations by leading experts in the fields of
cancer and inflammation. In addition, the Boston meeting presented
three Young Investigator awards, one in each of the major focus
areas. The meeting was exciting and proved to be very memorable.
The program was developed with an emphasis on recent advances in
molecular and of lipid mediators relevant in cellular mechanisims
involved in the formation and actions inflammation and cancer.
Plenary lectures were presented by Prof. Bengt Sammuelsson
(Karolinska Institute, Stockholm; 1982 Nobel Laureate in Physiology
or Medicine) and Prof. E. 1. Corey (Harvard University; 1990 Nobel
Laureate in Chemistry). Both of these plenary lectures were held on
Day 1, which set an exciting tone for this meeting. Immediately
following these plenary lectures, three simultaneous breakout
sessions were held, one of inflammation, a second on cancer and
synthesis of novel inhibitors, and a third on
enzymes-lipoxygenases/cyclooxygenases and inhibitors.
This volume constitutes, in part, the proceedings of the Hong Kong
Conference on "Eicosanoids and Other Bioactive Lipids in Cancer,
Inflammation, and Radiation Injury" held in Hong Kong in October
1995. It contains papers by the symposium speakers, as well as
poster contributions from researchers in this field. Since the
discovery of "PROSTAGLANDIN-LIKE' substances 60 years ago. much has
been learned. EICOSANOID is the new term that is used to include
prostaglandins. thromboxanes, leukotrienes, lipoxins, isoprostanes,
depoxilins, hydroxy acids, epoxy and hydroperoxy fatty acids. The
conference focussed on recent development in underatanding the role
of EICOSANOIDS in inflammation, cancer, and radiation damage. At
the confer- ence, we also highlighted advances in newly developing
areas such as "NO," "A POP- TOSIS and "ANANDAMIDE." The discovery
of the structures of genes that encode several key enzymes and
receptors of the Eicosanoid cascade, has allowed us to include
reports in the "Alteration of the Gene Expression" section that
reflects the most recent de- velopments in regulation for
PGH-synthase and lipoxygenases. The editors are convinced that this
volume will be an up-to-date and useful reference for investigators
in both basic and clinical research.
In recent decades eicosanoids have been attracting an increasing
amount of attention as a result of their important physiological
roles in many areas of biology and medicine. The eicosanoids
comprise the prostaglandins, thromboxanes and leukotrienes and are
products of arachidonic acid, an essential polyunsaturated fatty
acid stored in tissue phospholipids. Disturbances of eicosanoids
and their metabolic products play a regulatory role in many types
of cell injuries and diseases. One of the most exciting areas of
eicosanoid research pinpoints their participation in the control of
cell proliferation and differentiation. Eicosanoids form a link
between different fields of research into such areas as cancer,
inflammation and radiation-induced injury. This link provided the
impetus for the development of the conference series of which the
present volume represents the proceedings of the Second
International Conference, held in Berlin in October 1991.
Over one hundred contributions detail advances in the molecular and
cellular biology of eicosanoid production, as well as their role in
signal transduction. One of the most exciting developments explored
within this collection of articles is the expression of the novel
isoform of cyclooxygenase (cox-2), which may play a large role in
the development of anti-inflammatory drugs.
The past twenty years have witnessed significant advances in the
treatment of cancer by surgery and radiation therapy. Gains with
cytotoxic chemotherapy have been much more modest. Of the
approximately 900,000 newly diagnosed cases of cancer each year,
50010 result in death of the patient. The primary cause of these
deaths is metastasis. Although the term metastasis was first coined
by Recamier in 1829, only in the past ten years have there been
intensive scientific investigations into the mechanisms by which
tumor cells metastasize. What has emerged is a complex process of
host-tumor cell interactions which has been termed the metastatic
cascade. Due to the complexity of the metastatic process, the study
of metastasis is multifaceted and involves elements of such areas
as differentiation, en zymology, genetics, hematology, immunology,
membrane biochemistry and molecular biology. The major objectives
of this book were to present the most recent advances in our
understanding of how tumor cells metastasize to secondary sites by
the leading experts in the biology of tumor invasion and
metastasis. We hope that this book will lead to new concepts for
the treatment of subclinical metastatic cancer. The chapters in
this book address both the basic science of metastasis and
potential clinical therapies directed toward interruption of the
metastatic cascade or toward eradication of subclinical metastases.
Many relevant topics have been omitted due to space considerations
and thus the topics included reflect the prej udices of the
editors."
This volume contains the proceedings of the First International
Conference on Eicosanoids and Other Bioactive Lipids in Cancer and
Radiation Injury held in Detroit, Michigan on October 11-14, 1989.
The program consisted of 83 oral and 29 poster presentations, 74 of
which are included in these proceedings. The major sponsors of the
conference were the Armed Forces Radiobiology Research Institute,
located in Bethesda, Maryland, the Radiation Oncology Research and
Development Center of the Gershenson Radiation Oncology Center,
Harper Hospital in Detroit, Michigan, and Schering AG of West
Germany. Eighteen other organizations provided additional support.
The conference was unique in its attempt to link the eicosanoid and
lipid researchers in the radiobiology and cancer disciplines. The
diverse roles that eicosanoids and other bioactive lipids play in
these biological phenomena including the participation of lipid
oxidation in conversion of procarcinogens, positive and negative
modulation of tumor growth, immunomodulation, tissue injury, and
yet protection and enhancement of cancer therapy, necessitated
scientific interaction to sort out and understand these complex and
sometimes contradictory observations. The success of this effort is
reflected not only through these proceedings, but also through the
decision to continue the conference series with a second meeting to
be held in Berlin between September 17-21, 1991.
In recent years the pace of research in prostate cancer has
increased dramatically. Creative ideas in combination with new and
emerging technologies have led to an explosion of discovery. These
types of advances in prostate cancer research presage an era of new
treatment strategies based on an understanding of the cellular and
molecular mechanisms of disease.
In creating this book, we aimed to cover a broad "bench to bedside"
research spectrum ranging from: genetic, molecular and cellular
analyses to epidemiological studies, refinements in local treatment
strategies and new biologically based non-hormonal treatments for
systemic disease.
Researchers and clinicians will find in this book a group of timely
and clinically relevant chapters on prostate cancer research and
treatment.
This volume represents a collection of contributions from the 6th
International Conference on Eicosanoids and Other Bioactive Lipids
in Cancer, Inflammation, and Related Diseases held in Boston from
September 12-15, 1999. The mission of this meeting was to bring
together senior and junior investigators to both announce and
examine their recent advancements in cutting-edge research on the
roles and actions of lipid mediators and their impact in human
physiology and disease pathogenesis. The meeting focused on new
concepts in these areas of interest to both clinicians and
researchers. The program included several outstanding plenary
lectures and presentations by leading experts in the fields of
cancer and inflammation. In addition, the Boston meeting presented
three Young Investigator awards, one in each of the major focus
areas. The meeting was exciting and proved to be very memorable.
The program was developed with an emphasis on recent advances in
molecular and of lipid mediators relevant in cellular mechanisims
involved in the formation and actions inflammation and cancer.
Plenary lectures were presented by Prof. Bengt Sammuelsson
(Karolinska Institute, Stockholm; 1982 Nobel Laureate in Physiology
or Medicine) and Prof. E. 1. Corey (Harvard University; 1990 Nobel
Laureate in Chemistry). Both of these plenary lectures were held on
Day 1, which set an exciting tone for this meeting. Immediately
following these plenary lectures, three simultaneous breakout
sessions were held, one of inflammation, a second on cancer and
synthesis of novel inhibitors, and a third on
enzymes-lipoxygenases/cyclooxygenases and inhibitors.
This volume constitutes, in part, the proceedings of the Hong Kong
Conference on "Eicosanoids and Other Bioactive Lipids in Cancer,
Inflammation, and Radiation Injury" held in Hong Kong in October
1995. It contains papers by the symposium speakers, as well as
poster contributions from researchers in this field. Since the
discovery of "PROSTAGLANDIN-LIKE' substances 60 years ago. much has
been learned. EICOSANOID is the new term that is used to include
prostaglandins. thromboxanes, leukotrienes, lipoxins, isoprostanes,
depoxilins, hydroxy acids, epoxy and hydroperoxy fatty acids. The
conference focussed on recent development in underatanding the role
of EICOSANOIDS in inflammation, cancer, and radiation damage. At
the confer- ence, we also highlighted advances in newly developing
areas such as "NO," "A POP- TOSIS and "ANANDAMIDE." The discovery
of the structures of genes that encode several key enzymes and
receptors of the Eicosanoid cascade, has allowed us to include
reports in the "Alteration of the Gene Expression" section that
reflects the most recent de- velopments in regulation for
PGH-synthase and lipoxygenases. The editors are convinced that this
volume will be an up-to-date and useful reference for investigators
in both basic and clinical research.
This volume contains the proceedings of the First International
Conference on Eicosanoids and Other Bioactive Lipids in Cancer and
Radiation Injury held in Detroit, Michigan on October 11-14, 1989.
The program consisted of 83 oral and 29 poster presentations, 74 of
which are included in these proceedings. The major sponsors of the
conference were the Armed Forces Radiobiology Research Institute,
located in Bethesda, Maryland, the Radiation Oncology Research and
Development Center of the Gershenson Radiation Oncology Center,
Harper Hospital in Detroit, Michigan, and Schering AG of West
Germany. Eighteen other organizations provided additional support.
The conference was unique in its attempt to link the eicosanoid and
lipid researchers in the radiobiology and cancer disciplines. The
diverse roles that eicosanoids and other bioactive lipids play in
these biological phenomena including the participation of lipid
oxidation in conversion of procarcinogens, positive and negative
modulation of tumor growth, immunomodulation, tissue injury, and
yet protection and enhancement of cancer therapy, necessitated
scientific interaction to sort out and understand these complex and
sometimes contradictory observations. The success of this effort is
reflected not only through these proceedings, but also through the
decision to continue the conference series with a second meeting to
be held in Berlin between September 17-21, 1991.
Over one hundred contributions detail advances in the molecular and
cellular biology of eicosanoid production, as well as their role in
signal transduction. One of the most exciting developments explored
within this collection of articles is the expression of the novel
isoform of cyclooxygenase (cox-2), which may play a large role in
the development of anti-inflammatory drugs.
The past twenty years have witnessed significant advances in the
treatment of cancer by surgery and radiation therapy. Gains with
cytotoxic chemotherapy have been much more modest. Of the
approximately 900,000 newly diagnosed cases of cancer each year,
50010 result in death of the patient. The primary cause of these
deaths is metastasis. Although the term metastasis was first coined
by Recamier in 1829, only in the past ten years have there been
intensive scientific investigations into the mechanisms by which
tumor cells metastasize. What has emerged is a complex process of
host-tumor cell interactions which has been termed the metastatic
cascade. Due to the complexity of the metastatic process, the study
of metastasis is multifaceted and involves elements of such areas
as differentiation, en zymology, genetics, hematology, immunology,
membrane biochemistry and molecular biology. The major objectives
of this book were to present the most recent advances in our
understanding of how tumor cells metastasize to secondary sites by
the leading experts in the biology of tumor invasion and
metastasis. We hope that this book will lead to new concepts for
the treatment of subclinical metastatic cancer. The chapters in
this book address both the basic science of metastasis and
potential clinical therapies directed toward interruption of the
metastatic cascade or toward eradication of subclinical metastases.
Many relevant topics have been omitted due to space considerations
and thus the topics included reflect the prej udices of the
editors."
This book provides an updated overview of eicosanoid metabolism. It
also presents a timely discussion of eicosanoid metabolism in the
process of tumor cell metastasis, in chemoprotection and
radioprotection associated with cancer therapy, and in cell
differentiation. The book focuses on the role of eicosanoids in the
immunology of malignant disease. This includes how various immune
cell populations in cancer are affected by the secretion and action
of various eicosanoids and metabolites of eicosanoids and how these
processes may be affected by various pharmacological manipulations
and interventions to augment anti-tumor immunity. Head and neck
cancer is covered in great detail to illustrate a cancer in humans
where these considerations are particularly relevant. This
important volume demonstrates that the principal factor in cancer
patient immunologic deficiency is related to excess secretion by
monocytes of prostaglandins.
In recent years the pace of research in prostate cancer has
increased dramatically. Creative ideas in combination with new and
emerging technologies have led to an explosion of discovery. These
types of advances in prostate cancer research presage an era of new
treatment strategies based on an understanding of the cellular and
molecular mechanisms of disease.
In creating this book, we aimed to cover a broad "bench to bedside"
research spectrum ranging from: genetic, molecular and cellular
analyses to epidemiological studies, refinements in local treatment
strategies and new biologically based non-hormonal treatments for
systemic disease.
Researchers and clinicians will find in this book a group of timely
and clinically relevant chapters on prostate cancer research and
treatment.
|
|